Zevra Therapeutics Says FDA Accepts Resubmission Of Arimoclomol NDA In Niemann-Pick Disease Type C

Rare disease therapeutics company Zevra Therapeutics, Inc. (ZVRA) announced Monday that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the New Drug Application (NDA) for arimoclomol as an orally-delivered, first-in-class treatment for Niemann-Pick disease type C.

Related Keywords

,Drug Administration ,Zevra Therapeutics Inc ,Zevra Therapeutics ,New Drug Application ,Prescription Drug User Fee Act ,Fda ,Us Food And Drug Administration ,Pdufa ,Rimoclomol ,Niemann Pick Disease Type C ,Nvra ,Are Disease Therapeutics Company Zevra ,